<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Berthold</forename><surname>Hocher</surname></persName>
							<email>hocher@uni-potsdam.de</email>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Institut für Laboratoriumsmedizin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany,</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Basic Medicine</orgName>
								<orgName type="institution">Medical College of Hunan Normal University</orgName>
								<address>
									<settlement>Changsha</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Reichetzeder</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karoline</forename><surname>Von Websky</surname></persName>
							<idno type="ORCID">0000-0002-2219-5529</idno>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oleg</forename><surname>Tsuprykov</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Institut für Laboratoriumsmedizin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany,</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Azadeh</forename><forename type="middle">Mohagheghi</forename><surname>Samarin</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute of Aquaculture</orgName>
								<orgName type="institution">University of South Bohemia</orgName>
								<address>
									<settlement>České Budějovice</settlement>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Czech Republic</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luise</forename><forename type="middle">Gabriele</forename><surname>Falke</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sulistyo</forename><surname>Emantoko</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dwi</forename><surname>Putra</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Faculty of Biotechnology</orgName>
								<orgName type="institution">University of Surabaya</orgName>
								<address>
									<settlement>Surabaya</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmed</forename><forename type="middle">Abdallah</forename><surname>Hasan</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Biochemistry</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Zagazig University</orgName>
								<address>
									<settlement>Zagazig</settlement>
									<country key="EG">Egypt</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Viktoriia</forename><surname>Antonenko</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Nuthetal, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Caterina</forename><surname>Curato</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Cluster of Excellence NeuroCure</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jörg</forename><surname>Rippmann</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">Cardio Metabolic Diseases</orgName>
								<orgName type="institution" key="instit2">Boehringer-Ingelheim Pharma GmbH&amp;Co KG</orgName>
								<address>
									<settlement>Biberach, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Klein</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">Cardio Metabolic Diseases</orgName>
								<orgName type="institution" key="instit2">Boehringer-Ingelheim Pharma GmbH&amp;Co KG</orgName>
								<address>
									<settlement>Biberach, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<addrLine>Arthur-Scheunert-Allee 114-116</addrLine>
									<postCode>14558</postCode>
									<settlement>Nuthetal, Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">93A33F4AA16B7DD1CAB3487B1B365CDC</idno>
					<idno type="DOI">10.1111/bph.13822</idno>
					<note type="submission">Received 25 July 2016; Revised 2 April 2017; Accepted 5 April 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:29+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>AKI, acute kidney injury</term>
					<term>CKD, chronic kidney disease</term>
					<term>DPP4, dipeptidyl peptidase 4</term>
					<term>ESRD, end-stage renal disease</term>
					<term>GIP, gastric inhibitory polypeptide</term>
					<term>GLP-1, glucagon-like peptide type 1</term>
					<term>IRI, ischaemia reperfusion injury</term>
					<term>KC, keratinocyte chemoattractant</term>
					<term>MCP-1, monocyte chemotactic protein 1</term>
					<term>UniNX, uni-nephrectomy</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BACKGROUND AND PURPOSE</head><p><s>Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting.</s><s>Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EXPERIMENTAL APPROACH</head><p><s>IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min.</s><s>The sham group was uninephrectomized but not subjected to IRI.</s><s>DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg•kg À1 •day À1 ), vildagliptin (8 mg•kg À1 •day À1 ) and sitagliptin (30 mg•kg À1 •day À1 ).</s><s>An additional group received sitagliptin until study end (before IRI: 30 mg•kg À1 •day À1 ; after IRI: 15 mg•kg À1 •day À1 ).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>KEY RESULTS</head><p><s>Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI.</s><s>Plasma cystatin C, a marker of GFR, peaked 48 h after IRI.</s><s>Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels.</s><s>DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies.</s><s>Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors.</s><s>IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition.</s><s>Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group.</s><s>Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS AND IMPLICATIONS</head><p><s>In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Acute kidney injury (AKI) is a frequent and increasingly prevalent syndrome, defined by a rapid deterioration of kidney function <ref type="bibr" target="#b30">(Kam Tao Li et al., 2013;</ref><ref type="bibr" target="#b35">Kramann et al., 2015)</ref>, which is associated with high morbidity and mortality <ref type="bibr" target="#b36">(Lafrance and Miller, 2010;</ref><ref type="bibr" target="#b30">Kam Tao Li et al., 2013)</ref>.</s><s>The incidence of AKI is increasing and expected to double over the next 10 years <ref type="bibr" target="#b54">(Silver et al., 2015)</ref>.</s><s>Data from recent observational studies suggest an association between AKI and chronic kidney disease (CKD) and end-stage renal disease (ESRD) <ref type="bibr" target="#b15">(Coca et al., 2012)</ref>.</s><s>About 14% of patients with AKI progress to stage 4 CKD, and more severe cases of AKI are associated with a higher risk for progression into CKD <ref type="bibr" target="#b12">(Chawla et al., 2011;</ref><ref type="bibr" target="#b15">Coca et al., 2012)</ref>.</s><s>The high incidence of AKI is discussed as one possible explanation for the increasing burden of CKD and ESRD <ref type="bibr" target="#b15">(Coca et al., 2012;</ref><ref type="bibr" target="#b5">Belayev and Palevsky, 2014)</ref>.</s><s>There are many risk factors and causes for AKI <ref type="bibr" target="#b26">(Hsu et al., 2008;</ref><ref type="bibr" target="#b4">Basile et al., 2012)</ref>.</s><s>Among these, the most prominent aetiology of AKI is acute tubular necrosis as a consequence of an ischaemic or nephrotoxic insult <ref type="bibr" target="#b4">(Basile et al., 2012;</ref><ref type="bibr" target="#b35">Kramann et al., 2015)</ref>.</s><s>In a clinical setting, kidney hypoxia or ischaemia-reperfusion injury (IRI) inevitably occurs during surgery involving renal or aortic vascular occlusion.</s><s>Of all cases of hospital-acquired AKI, approximately 30-40% occur during surgery, making the perioperative period one of the leading causes of AKI <ref type="bibr" target="#b62">(Uchino et al., 2005;</ref><ref type="bibr" target="#b56">Thakar et al., 2009)</ref>.</s><s>The most vulnerable renal tissue with regards to both ischaemic and toxic insults are tubular epithelial cells <ref type="bibr" target="#b8">(Bonventre and Yang, 2011;</ref><ref type="bibr" target="#b35">Kramann et al., 2015)</ref>.</s><s>These cells rely on aerobic respiration and have a high metabolic demand due to their involvement in fluid and electrolyte reabsorption, making them uniquely susceptible to IRI <ref type="bibr" target="#b61">(Uchida and Endou, 1988;</ref><ref type="bibr" target="#b35">Kramann et al., 2015)</ref>.</s></p><p><s>Dipeptidyl peptidase 4 (DPP4) inhibitors are a new drug class approved for the treatment of type 2 diabetes.</s><s>Its anti-diabetic effects are elicited by an inhibition of the ubiquitously expressed serine exopeptidase DPP4, which mediates the degradation of incretins such as glucagonlike peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) <ref type="bibr" target="#b38">(Mentlein, 1999)</ref>.</s><s>Moreover, DPP4 also has several other substrates, including growth factors, neuro-and vasoactive peptides and chemokines <ref type="bibr" target="#b38">(Mentlein, 1999)</ref>.</s><s>Based on the structure, DPP4 inhibitors can be broadly divided into peptidomimetics (e.g.</s><s>vildagliptin) and nonpeptidomimetics (e.g.</s><s>linagliptin, sitagliptin) <ref type="bibr" target="#b3">(Baetta and Corsini, 2011;</ref><ref type="bibr" target="#b9">Ceriello et al., 2014)</ref>.</s><s>Although their chemical structures are different, all DPP4 inhibitors are substrate competitive active site binders but show different binding characteristics on the DPP4 protein <ref type="bibr" target="#b53">(Schnapp et al., 2016)</ref>.</s></p><p><s>Preclinical evidence suggests that DPP4 inhibitors have protective effects on IRI of the heart and lungs <ref type="bibr" target="#b51">(Sauvé et al., 2010;</ref><ref type="bibr" target="#b28">Jungraithmayr et al., 2012;</ref><ref type="bibr" target="#b25">Hocher et al., 2013)</ref>.</s><s>As DPP4 is strongly expressed in the kidney <ref type="bibr" target="#b38">(Mentlein, 1999)</ref>, DPP4 inhibition might also elicit protective effects in renal IRI.</s><s>Several studies already investigated putative protective effects in renal IRI, but with conflicting results.</s><s>Therefore, we studied the effects of three structurally different DPP4 inhibitors -linagliptin, vildagliptin and sitagliptin -on the outcome of IR-induced AKI in uni-nephrectomized rats.</s><s>One additional arm (sitagliptin) was treated throughout the entire experiment and dose adjusted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p><s>All animal care and experimental procedures were approved by the Committee on the Ethics of Animal Experiments (Landesamt fuer Gesundheit und Soziales), Berlin, Germany.</s><s>Animal studies are reported in compliance with the ARRIVE guidelines <ref type="bibr" target="#b32">(Kilkenny et al., 2010;</ref><ref type="bibr" target="#b33">Kilkenny et al., 2012;</ref><ref type="bibr" target="#b37">McGrath &amp; Lilley, 2015)</ref>.</s><s>Male Wistar rats (10 sham animals, 14 placebo-treated animals and 14 per each treatment group), aged 5-6 weeks, weighing 200-250 g, were obtained from Charles River, Germany, and housed in groups under standardized specific pathogen-free conditions (12 h light/dark cycle, 23°C, humidity of 50-60%, rat type IV cages) with food and water ad libitum.</s><s>After an acclimatization period of 1 week, all animals were subjected to uni-nephrectomy.</s><s>Two weeks later, the remaining kidney was exposed to IRI by clamping the renal artery for 30 min, and sham surgery was performed without clamping.</s><s>Animals were randomly allocated to six different groups: sham, placebo, linagliptin (1.5 mg•kg À1 •day À1 ), vildagliptin (8 mg•kg À1 •day À1 ), sitagliptin (30 mg•kg À1 •day À1 ) and prolonged/dose-adjusted sitagliptin, a group which was treated with sitagliptin until the end of study in order to block the DPP4 activity during the entire experiment.</s><s>In this group, treatment started with 30 mg•kg À1 once daily on two consecutive days prior to IRI; after that, the dose was adjusted to 15 mg•kg À1 •day À1 because of renal failure.</s><s>All groups received DPP4 inhibitor treatment or vehicle via gavage once daily on two consecutive days prior to IRI and on the day of surgery 2 h before IRI.</s><s>Doses in the current study were selected based on previous DPP4 inhibitor studies in similar settings and calculated on AUC <ref type="bibr" target="#b13">(Chaykovska et al., 2011;</ref><ref type="bibr" target="#b16">Connelly et al., 2014)</ref>.</s></p><p><s>Baseline blood samples were taken from the tail vein.</s><s>Blood samples were collected at baseline 24 h before IRI, and 24, 48, 72 h and 1 week (168 h) after IRI.</s><s>Afterwards, animals were killed under deep isoflurane anaesthesia and organs were harvested.</s><s>Two sham animals were excluded from the study because of critical weight loss occurring shortly after the surgical sham intervention (probably due to infection), reducing the n-value of the sham group to eight.</s><s>The n-value variation of measured plasma parameters among the analysed experimental groups originated from either limited plasma sample volume or from plasma samples that gave a NaN (not a number) result in the respective assay.</s><s>The n-value variation of histological readouts among the experimental groups occurred because of suboptimal tissue processing in one batch of samples due to technical difficulties of the automated tissue processor.</s><s>The whole animal experiment was performed in a randomized fashion using six arms.</s><s>Rats were randomly allocated to six different arms, with each arm containing about the same number of animals from every treatment group.</s><s>The animal study was performed by different investigators than the following experiments, ensuring that all analyses were performed in a blinded fashion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biomarkers of renal function and injury</head><p><s>Plasma cystatin C, a biomarker of glomerular filtration rate and osteopontin, a biomarker of tubular damage, were measured by automated immunoassays (Myriad RBM, Inc., Austin, Texas, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DPP4 activity and GLP-1 measurements</head><p><s>Whole blood was collected into lithium heparin-treated tubes and plasma was separated by centrifugation.</s><s>Activity of plasma DPP4 was assessed using a previously reported method <ref type="bibr" target="#b13">(Chaykovska et al., 2011)</ref>.</s><s>A 20 μL volume of plasma was diluted with 30 μL of DPP4 assay buffer (100 mmol•L À1 Tris, 100 mmol•L À1 NaCl, adjusted to pH 7.8 with HCl) and mixed with 50 μL substrate (final concentration 100 mmol•L À1 H-Ala-Pro-7-amido-4-trifluoromethylcoumarin).</s><s>After incubation at room temperature for 10 min, fluorescence of the wells was determined using a Wallac Victor 1420 Multilabel Counter at an excitation wavelength of 405 nm and an emission wavelength of 535 nm.</s><s>Active (uncleaved, 7-36 amide or 7-37) GLP-1 was detected in plasma samples using a commercially available multiarray assay system (K150JWC from Meso Scale Discovery, Rockwell, Maryland, USA) following the instructions provided by the supplier.</s><s>This antibody only detects active GLP-1 (7-36 amide or 7-37 GLP-1) but not cleaved and inactive GLP-1 (9-36 amide or 9-37 GLP-1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytokine detection from plasma and kidney homogenates</head><p><s>For preparation of kidney extracts, 50 mg of tissue was lysed in 500 μL of Meso Scale Discovery (Gaithersburg, MD, USA) lysis buffer (MSD R60TX-2) with protease inhibitor cocktails from Thermo Fisher, Germany (1861278), and Sigma, Germany (P5726), using FastPrep devices (MP Biomedicals) at 4°C, 30 s, 6000 × g.</s><s>Homogenates were centrifuged for 10 min, 4°C at 10 000 × g.</s><s>Supernatants were adjusted to protein concentration of 20 mg•mL À1 and used for cytokine analysis and DPP4 activity measurements.</s></p><p><s>Cytokine concentrations of kidney tissue (50 μL of lysate) and plasma samples (undiluted sample) were analysed by Meso Scale Discovery (Gaithersburg, MD, USA) immunoassays according to the manufacturer's protocols using a MSD Custom Rat Cytokine kit (K153AOH-2).</s><s>Concentrations of CCL2 were analysed in 25 μL aliquots by the Rat Mcp-1 Ultra Sensitive Kit (K153AYC-2).</s><s>Absolute concentrations were calculated by comparison with a series of standard dilutions of the respective cytokine measured on the same plate.</s><s>In both plasma and renal homogenates, concentrations of CCL2, IFNγ, IL-10, IL-13, IL-1β, IL-4, IL-5, IL-6, keratinocyte chemoattractant (KC) and TNF-α were analysed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal DPP4 activity</head><p><s>For DPP4 activity, 2 μL of kidney homogenate extracts were diluted with 130 mL of HEPES buffer (10 mM) pH 7.6 and incubated for 10 min at 37°C in 96-well plates.</s><s>A total of 100 μL of Gly-Pro-pNA (4-nitroaniline, Sigma Aldrich, Germany) was added as DPP4 substrate (1 mM solution) and kinetics (20 min, every 60 s) were detected at 405 nm.</s><s>The reaction was observed to be linear up until 11 min; thus, this timeframe was used to assess renal DPP4 activity.</s></p><p><s>Because Gly-Pro-pNA is an artificial DPP4 substrate and high protease activity is present in the kidney, we added 10 μM sitagliptin to a parallel set of extracts, to define DPP4-specific activity baseline.</s><s>Values were given as specific DPP4 activity in (δ OD405 nm•min À1 ) by subtracting sitagliptin-inhibited baseline.</s><s>For graphic display and statistical analysis, treatment group-specific AUC of the linear kinetic period (0-11 min) were calculated (minutes were converted to seconds).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histological assessment of kidney tubular necrosis and tubular dilatation</head><p><s>For pathohistological evaluation, all samples were embedded in paraffin, cut in 3 μm sections and stained with haematoxylin-eosin.</s><s>Tubular dilatation and tubular necrosis were analysed using a semiquantitative grading score on haematoxylin-eosin stained kidney samples by two blinded independent investigators.</s><s>At least 25 viewing fields of the outer medulla were randomly chosen with 200× magnification per each kidney sample.</s><s>Tubular dilatation was assessed by a three-point scoring system, where 1 indicates &lt;25% tubules show dilation and thinned epithelium, 2 indicates 25 to 50% tubules show dilation and thinned epithelium, and 3 indicates &gt;50% tubules show dilation and thinned epithelium <ref type="bibr" target="#b7">(Blydt-Hansen et al., 2003)</ref>.</s><s>Tubular necrosis was classified according to a 1-5 score as follows: grade 1 (no to mild damage) = less than 10% tubular necrosis, grade 2 (mild to moderate damage) = 10 to 25% tubular cell necrosis, grade 3 (moderate to severe damage) = 25 to 50% tubular cell necrosis, grade 4 (severe damage) = 50 to 75% and grade 5 (severe to very severe) = greater than 75% tubular cell necrosis <ref type="bibr" target="#b46">(Park et al., 2008)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blot analysis of renal protein expression</head><p><s>Western blots were performed as previously described <ref type="bibr" target="#b49">(Putra et al., 2014)</ref>.</s><s>Briefly, renal samples containing both cortex and medulla were crushed in a metal mortar after cooling in liquid nitrogen.</s><s>Protein was extracted using a urea/thiourea buffer [2 M thiourea, 7 M urea, 2% SDS, 1% DTT and protease inhibitor (Complete Mini, Cat.</s><s>no.: 11 697 498 001, Roche)].</s><s>Protein extracts were separated by SDS-PAGE employing a 10% polyacrylamide gel.</s><s>Following SDS-PAGE gels were blotted to nitrocellulose membrane (AmershamTM HybondTM ECL, GE Healthcare) using a Biorad Trans-Blot semidry blotter and transfer buffer (184 mM glycine, 24 mM Tris, 20% methanol).</s><s>The antiosteopontin antibody (sc-21742, Santa Cruz Biotechnology) was used at a dilution of 1:1000 and the anti-housekeeping protein actin antibody (A5060, Sigma-Aldrich) at a dilution of 1:10 000.</s><s>The signals were developed using enhanced chemiluminescence.</s><s>The developed membranes were digitalized using a 600 dpi scanner resolution and analysed with AlphaEaseFCTM.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology <ref type="bibr" target="#b17">(Curtis et al., 2015)</ref>.</s><s>Statistical analyses were performed using SPSS Version 20 and Graph Pad Prism 6.</s><s><ref type="table" target="#tab_1">British Journal of Pharmacology (2017) 174 2273-2286 2275</ref> Quantitative data in text and tables are expressed as mean ± SD.</s><s>In the figures, data are presented as means ± SEM.</s><s>Data were analysed for normal distribution using the Kolmogorov-Smirnov test.</s><s>Not normally distributed data were analysed using the Kruskal-Wallis test followed by a Dunn post hoc test.</s><s>For normally distributed data, group comparisons were performed employing one-way ANOVA.</s><s>Heterogeneity of variance was assessed using Levene's test.</s><s>If results of the test were significant (P &lt; 0.05), Welch's F was used.</s><s>According to heterogeneity of variances, either a Bonferroni (equal variances assumed) or a Games-Howell (unequal variances assumed) post hoc test was used, as recommended <ref type="bibr" target="#b21">(Field, 2013;</ref><ref type="bibr" target="#b40">Muth, 2014)</ref>.</s><s>Post hoc tests were only run if F achieved P &lt; 0.05.</s><s>For the comparison of parameters measured over time, two-way ANOVA was used followed by a Bonferroni post hoc test.</s><s>To analyse if two parameters are correlated, Pearson bivariate correlation analysis was employed.</s><s>P values lower than 0.05 were considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DPP4 inhibition in acute kidney injury BJP</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials</head><formula xml:id="formula_0">Linagliptin [BI1356; 8-[(3R)-aminopiperidin-1-yl]-7-(but-2-yn- 1-yl)-3-methyl-1-[(4-methyl-quinazolin-2-yl)methyl]-3,7-dihydr o-1H-purine-2,6-dione]</formula><formula xml:id="formula_1">(2S)-1-[2-[(3-hydroxy- 1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile] and sitagl- iptin [(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2, 4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-o ne]</formula><p><s>were from Sequoia, Oxford, UK.</s><s>The compounds were dissolved in 0.5% Natrosol, and were administered p.o.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nomenclature of targets and ligands</head><p><s>Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY <ref type="bibr" target="#b55">(Southan et al., 2016)</ref>, and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 <ref type="bibr" target="#b0">(Alexander et al., 2015)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Basic characteristics of the treatment groups are displayed in Table <ref type="table" target="#tab_0">1</ref>.</s><s>There were no statistical significant differences regarding baseline and final body weight.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kidney function</head><p><s>The impact of IRI on kidney function was assessed by plasma cystatin C and osteopontin levels.</s><s>IRI induced steadily increasing plasma cystatin C concentrations, which peaked 48 h after clamping.</s><s>The placebo group displayed significantly higher cystatin C levels 48 h after IRI compared with the sham group (Figure <ref type="figure">1A</ref>).</s><s>Treatment with DPP4 inhibitors did not significantly affect plasma cystatin C concentrations compared with placebo at any point (Figure <ref type="figure">1A</ref>).</s><s>Furthermore, IRI induced an increase in plasma osteopontin levels, which peaked 72 h after clamping (Figure <ref type="figure">1B</ref>).</s><s>Compared with the sham group, the placebo group displayed significantly elevated plasma osteopontin levels at 24 h, 48 h and 72 h after clamping (Figure <ref type="figure">1B</ref>).</s><s>Treatment with DPP4 inhibitors resulted in numerically lower plasma osteopontin concentrations compared with the placebo group, but these differences did not reach statistical significance at any point (Figure <ref type="figure">1B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DPP4 activity and active GLP-1 levels in plasma</head><p><s>All groups with DPP4 inhibitor treatment displayed a significantly reduced DPP4 activity 24 h after induction of IRI compared with the placebo group (Figure <ref type="figure" target="#fig_1">2A</ref>).</s><s>Plasma concentrations of active GLP-1 were significantly increased in all DPP4 inhibitor treatment groups versus the placebo group, up to 24 h after IRI (Figure <ref type="figure" target="#fig_1">2B</ref>).</s><s>At the end of the study, 168 h after IRI, active GLP-1 plasma concentrations of all treatment groups except the prolonged/dose-adjusted sitagliptin group returned to baseline.</s><s>The prolonged/dose-adjusted sitagliptin group, as expected, still displayed significantly elevated active GLP-1 plasma levels (Figure <ref type="figure" target="#fig_1">2C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal DPP4 activity</head><p><s>The AUC of renal DPP4 activity, assessed 168 h after IRI, was not significantly different between the sham and placebo group.</s><s>Kidney homogenates of linagliptin-treated animals still displayed a significantly reduced DPP4 activity compared with placebo-treated animals.</s><s>Also renal DPP4 activity of prolonged/dose-adjusted sitagliptin-treated animals was numerically reduced, but did not reach statistical significance.</s><s>Vildagliptin-and sitagliptin-treated animals displayed no reduction of renal DPP4 activity (Figure <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kidney morphology</head><p><s>Kidney weight, both absolute and in relation to body weight, was significantly increased in the placebo group compared with the sham group (Table <ref type="table" target="#tab_0">1</ref>).</s><s>IRI caused a significant increase of the tubular necrosis and tubular dilatation score in the placebo group compared with the sham group (Table <ref type="table" target="#tab_0">1</ref>; Figure <ref type="figure" target="#fig_4">4B</ref>).</s><s>The prolonged/dose-adjusted treatment with sitagliptin led to a significant decrease of both tubular necrosis and dilatation.</s><s>Regular sitagliptin treatment significantly reduced tubular dilatation, but only numerically affected tubular necrosis score.</s><s>Also linagliptin treatment resulted in a non-significant, numerically decreased tubular necrosis and dilatation score, whereas vildagliptin treatment was without effect (Table <ref type="table" target="#tab_0">1</ref>; Figure <ref type="figure" target="#fig_4">4C</ref>).</s><s>Furthermore, to assess the validity of the histological data, a correlation analysis was performed between peak plasma cystatin C (48 h) and peak plasma osteopontin (72 h) concentrations and tubular necrosis score.</s><s>Peak plasma cystatin C concentrations showed only a marginal correlation (Figure <ref type="figure" target="#fig_5">5A</ref>), while peak plasma osteopontin levels were strongly and significantly correlated with the extent of tubular necrosis and dilatation (Figure <ref type="figure" target="#fig_5">5B</ref>).</s><s>Based on the</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1</head><p><s>Concentrations of plasma cystatin C and osteopontin over the course of the study.</s><s>(A) Plasma cystatin C concentrations; n-values: sham (0 h: n = 8; 24 h: n = 8; 48 h: n = 8; 72 h: n = 8; 168 h: n = 8), placebo (0 h: n = 12; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 14), linagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 13; 168 h: n = 14), vildagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 14), sitagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 13), prolonged/dose-adjusted sitagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 14).</s><s>Values shown are means ± SEM. *P &lt; 0.05, significantly different as indicated; two-way ANOVA.</s><s>(B) Plasma osteopontin concentrations; n-values: sham (0 h: n = 8; 24 h: n = 8; 48 h: n = 8; 72 h: n = 8; 168 h: n = 8), placebo (0 h: n = 12; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 14), linagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 13; 168 h: n = 14), vildagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 14), sitagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 13), prolonged/ dose-adjusted sitagliptin (0 h: n = 14; 24 h: n = 14; 48 h: n = 14; 72 h: n = 14; 168 h: n = 14).</s><s>Values shown are means ± SEM. *P &lt; 0.05, significantly different as indicated; two-way ANOVA.</s></p><p><s>observation of a strong positive correlation between plasma osteopontin concentrations and the extent of tubular damage, together with a trend towards a reduction of plasma osteopontin by DPP4 inhibition, renal expression of osteopontin was analysed by Western blot (Figure <ref type="figure" target="#fig_6">6A, B</ref>).</s><s>Compared with the sham group, renal osteopontin expression was significantly increased in the placebo group.</s><s>DPP4 inhibition prevented any increases in renal osteopontin levels, leading to significantly reduced osteopontin levels compared with the placebo group in all DPP4 inhibitor treatment groups (Figure <ref type="figure" target="#fig_6">6A, B</ref>).</s><s>Contrary to plasma osteopontin, renal osteopontin levels were not correlated to the extent of tubular damage (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plasma and renal cytokine levels</head><p><s>Analysis of cytokine levels in plasma collected at study end showed no significant alterations among all groups (Table <ref type="table">2</ref>).</s><s>However, the renal expression of several cytokines was differently regulated.</s><s>IRI lead to a significant up-regulation of CCL2, IL-1β, IL-5 and KC in placebo-treated animals compared with sham animals.</s><s>Linagliptin, vildagliptin and sitagliptin treatment did not result in any significant differences compared with the placebo group.</s><s>However, prolonged/dose-adjusted sitagliptin-treated animals showed significantly higher concentrations of IL-6 compared with the placebo group (Table <ref type="table">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the current study, the effects of the DPP4 inhibitors linagliptin, vildagliptin and sitagliptin on renal IRI were analysed.</s><s>DPP4 inhibition induced a reduced plasma DPP4 activity in all treatment groups, paralleled by an increase of active GLP-1 concentrations, 24 h after IRI.</s><s>Renal DPP4  activity measured at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group.</s><s>Plasma cystatin C concentrations peaked 48 h after IRI and were higher in the placebo group compared with the sham group.</s><s>Plasma osteopontin concentrations showed a peak at 72 h, with higher plasma levels in the placebo compared with the sham group.</s><s>DPP4 inhibitor treatment did not affect plasma cystatin C concentrations at any point but showed a trend towards a reduction of plasma osteopontin levels.</s><s>Histological evaluation of the kidney samples revealed tubular necrosis and tubular dilatation in all groups subjected to IRI.  observed in prolonged/dose-adjusted sitagliptin treated animals.</s><s>Taken together, DPP4 inhibition did not affect the impairment of glomerular function due to IRI, measured by assessing plasma cystatin C concentrations, but did provide beneficial effects, in terms of tubular damage.</s><s>One limitation of the current study, similar to the majority of previous studies <ref type="bibr" target="#b63">(Vaghasiya et al., 2011;</ref><ref type="bibr" target="#b24">Glorie et al., 2012;</ref><ref type="bibr" target="#b44">Nuransoy et al., 2015;</ref><ref type="bibr" target="#b68">Youssef et al., 2015)</ref>, is that no urinary parameters were investigated, which could have improved assessments of the effects of DPP4 inhibition in renal IRI on glomerular function.</s></p><p><s>To the best of our knowledge, there are six published studies and one conference abstract that investigated DPP4 inhibition in renal IRI <ref type="bibr" target="#b63">(Vaghasiya et al., 2011;</ref><ref type="bibr" target="#b18">Daniel et al., 2012;</ref><ref type="bibr" target="#b24">Glorie et al., 2012;</ref><ref type="bibr" target="#b14">Chen et al., 2013;</ref><ref type="bibr" target="#b10">Chang et al., 2015;</ref><ref type="bibr" target="#b44">Nuransoy et al., 2015;</ref><ref type="bibr" target="#b68">Youssef et al., 2015)</ref>.</s><s>Details of these studies are summarized in Table <ref type="table" target="#tab_1">3</ref>. Albeit employing a different assessment, quantitative and qualitative scoring systems, six of these studies were able to demonstrate a beneficial effect of DPP4 inhibition in renal IRI on tubular damage <ref type="bibr" target="#b63">(Vaghasiya et al., 2011;</ref><ref type="bibr" target="#b24">Glorie et al., 2012;</ref><ref type="bibr" target="#b14">Chen et al., 2013;</ref><ref type="bibr" target="#b10">Chang et al., 2015;</ref><ref type="bibr" target="#b44">Nuransoy et al., 2015;</ref><ref type="bibr" target="#b68">Youssef et al., 2015)</ref>.</s><s>Results of the current study substantiate these previous findings.</s><s>In regard to beneficial effects of DPP4 inhibition on glomerular function, two studies, both investigating sitagliptin in renal IRI, also did not demonstrate any significant results <ref type="bibr" target="#b10">(Chang et al., 2015;</ref><ref type="bibr" target="#b44">Nuransoy et al., 2015)</ref>.</s><s>Four other studies did observe significant effects of DPP4 inhibition on glomerular function <ref type="bibr" target="#b63">(Vaghasiya et al., 2011;</ref><ref type="bibr" target="#b24">Glorie et al., 2012;</ref><ref type="bibr" target="#b14">Chen et al., 2013;</ref><ref type="bibr" target="#b68">Youssef et al., 2015)</ref>.</s><s>However, both conflicting and supporting data have to be interpreted carefully, as the designs of all the available studies are very heterogeneous (Table <ref type="table" target="#tab_1">3</ref>).</s><s>In a study of <ref type="bibr" target="#b63">Vaghasiya et al. (2011)</ref>, the authors did show protective effects of DPP4 inhibition on glomerular function, but only in a diabetic rat model of renal IRI.</s><s><ref type="bibr" target="#b24">Glorie et al. (2012)</ref>, using a non-diabetic rat model (left renal pedicle clamping for 30 min followed by right nephrectomy), induced mild renal impairment with peak glomerular dysfunction 12 h after IRI.</s><s>The authors demonstrated a significant reduction of serum creatinine at 12 h and to a minor extent at 48 h after IRI.</s><s>Contrary to all other available studies that used oral drug administration, vildagliptin was administered intravenously 15 min prior to IRI <ref type="bibr" target="#b24">(Glorie et al., 2012)</ref>.</s><s><ref type="bibr" target="#b14">Chen et al. (2013)</ref> did observe positive effects of DPP4 inhibition on parameters of glomerular function, yet excessive supratherapeutic doses of sitagliptin (600 mg•kg À1 •day À1 ) were used, which might elicit a positive effect on renal function in this animal model, but could possibly pose a risk and would be hard to translate to humans <ref type="bibr" target="#b6">(Bloomfield et al., 2009)</ref>.</s><s>Setting results of the current study into context with results from comparable studies <ref type="bibr" target="#b24">(Glorie et al., 2012;</ref><ref type="bibr" target="#b68">Youssef et al., 2015)</ref>, it has to be taken into account that in the current study, different to all previous studies, IRI was induced 2 weeks after uninephrectomy, in a state of mild renal impairment (Arsenijevic  <ref type="bibr">et al., 2015)</ref>.</s><s>It has been shown that this additional insult results in a more pronounced post-ischaemic functional impairment, which could have masked minor positive effects of DPP4 inhibition <ref type="bibr" target="#b64">(Vercauteren et al., 1999)</ref>.</s><s>However, inducing renal IRI on top of mild renal impairment might represent the clinical situation better, as impaired renal function is a strong risk factor for acute renal failure, and the prevalence for acute renal failure in healthy individuals is low <ref type="bibr" target="#b26">(Hsu et al., 2008)</ref>.</s><s>Furthermore, the different DPP4 inhibitor dosing, treatment timing and pharmacokinetic profiles must also be considered as other factors influencing the study results (Table <ref type="table" target="#tab_1">3</ref>).</s><s>Vildagliptin, for example, has a considerably lower IC 50 towards DPP-8 and DPP-9 than other DPP4 inhibitors, as has linagliptin towards fibroblast activating protein <ref type="bibr" target="#b57">(Thomas et al., 2008;</ref><ref type="bibr" target="#b27">Huan et al., 2015)</ref>.</s><s>Depending on the drug doses used, together with putative disease-related expression changes, different outcomes in animal studies might be observed.</s><s>Furthermore, there are differences in the pharmacokinetics of DPP4 inhibitors.</s><s>In the current study, renal DPP4 activity was measured at study end 168 h after induction of IRI.</s><s>Although linagliptin treatment was discontinued on the day of IRI induction, renal DPP4 activity was still significantly inhibited 1 week later.</s><s>This reduction of renal DPP4 activity was not accompanied by increased plasma active GLP-1 levels, suggesting a minor role of renal DPP4 in inactivating circulating GLP-1 levels.</s><s>Contrary to data from the linagliptin group, no significant inhibition could be observed in the vildagliptin and sitagliptin group.</s><s>The prolonged and dose-adjusted sitagliptin group only showed a trend towards reduced renal DPP4 activity, but displayed significantly increased active GLP-1 plasma levels.</s><s>A possible explanation of the different renal DPP4 inhibition can be based on pharmacokinetic properties.</s><s>Linagliptin exhibits a 10-15 times greater apparent volume of distribution, with a higher tissue-to-blood ratio and more than 1000-fold lower k off rate from the DPP4 protein compared with sitagliptin <ref type="bibr" target="#b22">(Filippatos et al., 2014;</ref><ref type="bibr" target="#b27">Huan et al., 2015;</ref><ref type="bibr" target="#b41">Nakamaru et al., 2016;</ref><ref type="bibr" target="#b53">Schnapp et al., 2016)</ref>.</s><s>Regardless of renal DPP4 activity, the strongest effects on tubular damage were observed in the prolonged/dose-adjusted sitagliptin group.</s><s>In this group, contrary to all other treatment groups, active GLP-1 levels were increased until the end of the study, which, in context with previous findings, could be one underlying mechanism <ref type="bibr" target="#b10">(Chang et al., 2015)</ref>.</s><s>In summary, different models of IRI, different study durations and different drug dosing, employing structurally different DPP4 inhibitors, could have been influential factors underlying the different results in AKI settings with regards to DPP4 inhibition, IRI and glomerular function.</s><s>Another important reason for the observed heterogeneity in study results might be that current clinical definitions of AKI are focused on changes of glomerular function, by measuring suitable surrogate parameters, such as creatinine or cystatin C <ref type="bibr" target="#b31">(Kellum, 2015)</ref>.</s><s>These definitions ignore the actual morphological consequences of renal IRI, which is an impairment of tubular function due to tubular alterations such as tubular necrosis and tubular dilatation <ref type="bibr" target="#b50">(Racusen and Solez, 1986;</ref><ref type="bibr" target="#b20">Endre et al., 2013)</ref>.</s><s>In the current study, IRI had a modest effect on increasing plasma cystatin C, although tubular damage was very pronounced.</s><s>Furthermore, correlation analysis displayed only a weak positive association between plasma cystatin C and tubular necrosis but a very strong positive correlation between plasma osteopontin, a marker of tubular damage and tubular necrosis <ref type="bibr" target="#b66">(Xie et al., 2001;</ref><ref type="bibr" target="#b69">Zhang et al., 2010)</ref>.</s><s>A previous study showed that DPP4 inhibition leads to a reduction of plasma osteopontin levels <ref type="bibr" target="#b13">(Chaykovska et al., 2011)</ref>.</s><s>Also in the current study, DPP4 inhibition lowered plasma osteopontin levels, but this effect did not reach statistical significance.</s><s>However, the most pronounced effect in this regard was observed for the prolonged/dose-adjusted sitagliptin treatment, which also was associated with the strongest amelioration of histomorphological tubular damage and the only group with significantly elevated active GLP-1 plasma levels until study end.</s><s>This might indicate an advantage of a prolonged treatment regimen.</s><s>Analysis of renal osteopontin expression showed that osteopontin was significantly upregulated in the placebo group and uniformly downregulated to levels of the sham group in all DPP4 inhibitor groups.</s><s>To the best of our knowledge, this is the first observation of a down-regulating effect elicited by DPP4 inhibition on renal osteopontin expression.</s><s>Osteopontin, a secreted 44 kDa glycoprotein, is up-regulated in injured kidney cells and is involved in immune and anti-apoptotic processes next to a variety of other functions <ref type="bibr" target="#b66">(Xie et al., 2001)</ref>.</s><s>Previous studies have demonstrated that osteopontin expression is increased in renal IRI and that its modulation can alter the course of disease <ref type="bibr" target="#b45">(Padanilam et al., 1996;</ref><ref type="bibr" target="#b65">Wagner et al., 2003;</ref><ref type="bibr" target="#b69">Zhang et al., 2010)</ref>.</s><s>However, results are conflicting, attributing to osteopontin both a positive and a  negative impact on renal IRI <ref type="bibr" target="#b45">(Padanilam et al., 1996;</ref><ref type="bibr" target="#b42">Nambi et al., 1997;</ref><ref type="bibr" target="#b43">Noiri et al., 1999;</ref><ref type="bibr" target="#b47">Persy et al., 1999</ref><ref type="bibr" target="#b48">Persy et al., , 2003;;</ref><ref type="bibr" target="#b69">Zhang et al., 2010)</ref>.</s><s>Interpretation of results on osteopontin from the current study indicate a mild positive impact of reduced osteopontin levels in renal IRI, but leave room for speculation.</s></p><p><s>Other differently designed studies with kidney assessment at various earlier time points are needed to properly investigate the seemingly complex relationship between DPP4 inhibition, renal and plasma osteopontin levels and renal damage.</s><s>Given the role of osteopontin in inflammation, cytokine levels in plasma (obtained at study end) and cytokine levels in kidney homogenates were measured.</s><s>No significant changes in plasma cytokine levels could be observed, which might be due to the long interval between IRI and cytokine measurements (168 h post IRI).</s><s>Cytokine levels in renal homogenates of placebo-treated animals displayed a significant up-regulation of CCL2, IL-1β, IL-5 and KC levels.</s><s>DPP4 inhibitor treatment did not significantly affect these IRI-related changes in renal cytokine expression.</s><s>The prolonged/dose-adjusted sitagliptin group displayed a weak but significant up-regulation of renal IL-6 expression.</s><s>As an up-regulation of IL-6 was absent from the placebo group, the observed increase of IL-6 in the prolonged/dose-adjusted sitagliptin group, which displayed significantly elevated active GLP-1 plasma levels, might have been due to an GIP-mediated effect on IL-6 expression <ref type="bibr" target="#b19">(Ellingsgaard et al., 2011;</ref><ref type="bibr" target="#b58">Timper et al., 2013;</ref><ref type="bibr" target="#b29">Kahles et al., 2014;</ref><ref type="bibr" target="#b59">Timper et al., 2016)</ref>.</s></p><p><s>Taking into account that the design of the available studies of DPP4 inhibition in renal IRI is very heterogenous (Table <ref type="table" target="#tab_1">3</ref>), results of the current study are in agreement with previous studies, especially regarding beneficial effects of DPP4 inhibition on IRI-mediated tubular damage.</s><s>Although only some studies employed a quantitative assessment of histopathological kidney changes, all of the previously mentioned studies observed positive effects of DPP4 inhibition on histological readouts of kidney injury <ref type="bibr" target="#b63">(Vaghasiya et al., 2011;</ref><ref type="bibr" target="#b24">Glorie et al., 2012;</ref><ref type="bibr" target="#b14">Chen et al., 2013;</ref><ref type="bibr" target="#b10">Chang et al., 2015;</ref><ref type="bibr" target="#b44">Nuransoy et al., 2015;</ref><ref type="bibr" target="#b68">Youssef et al., 2015)</ref>.</s><s>One strength of the current study is the head-to-head comparison of several structurally unrelated DPP4 inhibitors, also in a clinical relevant regimen of dose adjustment.</s><s>Taken together, our data suggest DPP4 inhibition is safe in models of IRI and might elicit beneficial effects.</s><s>In this respect, a continuous treatment with DPP4 inhibitors or having patients on such drugs, when expecting an increased risk for AKI (e.g. during cardiac and transplantation surgeries) could be of benefit.</s><s>Detrimental effects of DPP4 deficiency, which were observed in DPP4deficient rats subjected to IRI <ref type="bibr" target="#b18">(Daniel et al., 2012)</ref>, were not observed by any other study including the current one.</s><s>This might be related to differences of a pharmacological inhibition of DPP4 in comparison with a full genetic knockout, probably due to missing crucial protein/protein interaction of DPP4 <ref type="bibr" target="#b39">(Mulvihill and Drucker, 2014)</ref>.</s><s>Results of the current study support earlier evidence that DPP4 inhibition exerts beneficial effects in renal tubules in models of IRI.</s><s>Regarding favourable effects of DPP4 inhibition on glomerular function, more homogenously designed studies, measuring the same parameters of glomerular function, are needed.</s></p><p><s>In conclusion, this study adds substantial evidence to previous findings, showing that DPP4 inhibition in IRI is safe and might exert beneficial effects on the renal tubules.</s><s>Clinical evaluation of the current findings is still missing, but results of this and previous studies in regard to drug safety could be of clinical importance.</s><s>Current evidence implies that no drug discontinuation would be needed in clinical situations with an elevated risk for renal IRI, such as cardiac surgery.</s><s>However, due to the impairment of renal function, dose adjustment would be necessary <ref type="bibr" target="#b52">(Scheen, 2015)</ref>.</s><s>From a practical point of view, this would favour linagliptin in a clinical setting, as it is the only DPP4 inhibitor, which does not need to be dose-adjusted in renal impairment <ref type="bibr" target="#b52">(Scheen, 2015)</ref>.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>was developed and synthesized by Boehringer Ingelheim Pharma GmbH and Co. KG (Biberach an der Riss, Germany), and vildagliptin [</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Plasma activity of DPP4 (A), plasma concentration of active GLP-1 24 h (B) and 168 h post IRI (C).</s><s>Values shown are means ± SEM. *P &lt; 0.05, significantly different as indicated; Kruskal-Wallis test or one-way ANOVA.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Renal DPP4 activity.</s><s>Mean area AUC was calculated for each treatment group-specific δ OD 405 nm•s À1 curve, and resulting mean values were analysed.</s><s>Values shown are means ± SEM. *P &lt; 0.05, significantly different as indicated; one-way ANOVA.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>DPP4 inhibition by prolonged/dose-adjusted sitagliptin treatment (and partly by regular sitagliptin treatment) reduced both tubular necrosis and dilatation.</s><s>Peak plasma cystatin C concentrations at 48 h were weakly correlated, and peak plasma osteopontin concentrations at 72 h were strongly correlated with the extent of tubular necrosis and dilatation.</s><s>Analysis of renal osteopontin expression revealed a significant reduction in all DPP4 inhibitor groups, compared with placebo.</s><s>Measurement of renal cytokine expression demonstrated an IRI-related up-regulation of CCL2, IL-1β, IL-5 and KC.</s><s>Furthermore, a significant up-regulation of renal IL-6 expression, which was absent in the placebo group, was</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4 Tubular dilatation and tubular necrosis score.</s><s>(A) Representative microphotographs from kidney sections of each treatment group.</s><s>(B) Tubular dilatation score.</s><s>(C) Tubular necrosis score.</s><s>Values shown are means ± SEM. *P &lt; 0.05, significantly different as indicated; one-way ANOVA.</s></p></div></figDesc><graphic coords="7,98.25,56.98,397.72,478.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5</head><label>5</label><figDesc><div><p><s>Figure 5Correlation between plasma cystatin C/osteopontin and tubular necrosis score.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 6</head><label>6</label><figDesc><div><p><s>Figure 6 Renal expression of osteopontin.</s><s>(A) Representative Western blot bands showing the expression of osteopontin (OPN, upper band; around 65 kDA) and the expression of actin (lower band; around 40 kDa).</s><s>(B) Protein expression of renal osteopontin (random units).</s><s>Values shown are means ± SEM. *P &lt; 0.05, significantly different as indicated; one-way ANOVA.</s></p></div></figDesc><graphic coords="9,42.58,56.98,240.07,246.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Basic animal characteristics and summary of kidney parameters</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Prolonged/</cell></row><row><cell></cell><cell>Sham</cell><cell>Placebo</cell><cell>Linagliptin</cell><cell>Vildagliptin</cell><cell>Sitagliptin</cell><cell>dose-adjusted</cell></row><row><cell></cell><cell>(8)</cell><cell>(14)</cell><cell>(14)</cell><cell>(14)</cell><cell>(14)</cell><cell>sitagliptin (14)</cell></row><row><cell>Baseline weight (g)</cell><cell>335.1 ± 10.7</cell><cell>333.1 ± 32.8</cell><cell>327.3 ± 24.1</cell><cell>327.1 ± 30.8</cell><cell>337.1 ± 21.6</cell><cell>321.3 ± 27.3</cell></row><row><cell>Final Weight (g)</cell><cell>362.4 ± 15.9</cell><cell>345.3 ± 26.4</cell><cell>344.9 ± 21.9</cell><cell>343.7 ± 28.0</cell><cell>351.6 ± 21.6</cell><cell>334.0 ± 28.8</cell></row><row><cell>Kidney Weight (g)</cell><cell>1.7 ± 0.2*</cell><cell>2.5 ± 0.7</cell><cell>2.3 ± 0.2</cell><cell>2.5 ± 0.5</cell><cell>2.4 ± 0.5</cell><cell>2.2 ± 0.3</cell></row><row><cell>Rel. Kidney Weight (g•g À1 BW × 100)</cell><cell>0.46 ± 0.04*</cell><cell>0.72 ± 0.17</cell><cell>0.66 ± 0.10</cell><cell>0.74 ± 0.12</cell><cell>0.68 ± 0.12</cell><cell>0.66 ± 0.12</cell></row><row><cell>Tubular dilatation score</cell><cell>1.1 ± 0.16*</cell><cell>2.8 ± 0.17</cell><cell>2.4 ± 0.41</cell><cell>2.8 ± 0.26</cell><cell>2.3 ± 0.46*</cell><cell>2.0 ± 0.52*</cell></row><row><cell>Tubular necrosis score</cell><cell>1.2 ± 0.15*</cell><cell>4.5 ± 0.48</cell><cell>4.0 ± 0.78</cell><cell>4.5 ± 0.62</cell><cell>3.6 ± 0.94</cell><cell>3.0 ± 1.03*</cell></row><row><cell>Renal osteopontin expression</cell><cell>0.75 ± 0.41*</cell><cell>1.17 ± 0.43</cell><cell>0.68 ± 0.22*</cell><cell>0.70 ± 0.34*</cell><cell>0.76 ± 0.34*</cell><cell>0.67 ± 0.29*</cell></row></table><note><p><s>*P &lt; 0.05, significantly different from placebo; one-way ANOVA.</s><s>Values displayed are means ± SD.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 3</head><label>3</label><figDesc><div><p><s>Studies investigating DPP4 inhibition in models of renal IRIStudy</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="9">DPP4 inhibition in acute kidney injury BJP</cell></row><row><cell>Overall</cell><cell></cell><cell cols="2">Tubular effects</cell><cell></cell><cell></cell><cell></cell><cell>Tubular and</cell><cell cols="2">glomerular effects</cell><cell></cell><cell cols="2">Tubular and</cell><cell cols="2">glomerular effects</cell><cell></cell><cell cols="2">Tubular effects</cell><cell></cell><cell cols="2">Tubular and</cell><cell cols="2">glomerular effects</cell><cell></cell><cell>Tubular and</cell><cell cols="2">glomerular effects</cell><cell>Detrimental tubular</cell><cell>and glomerular effects</cell></row><row><cell>Outcome</cell><cell>↓ Oxidative stress</cell><cell>↑ Antioxidative enzymes</cell><cell cols="2">↓ Tubular damage</cell><cell>↔ Serum creatinine 24 h post IRI</cell><cell>↓ Serum AST, creatinine, urea</cell><cell>nitrogen 24 h post IRI</cell><cell cols="2">↑ Antioxidative enzymes</cell><cell>↓ Tubular damage</cell><cell>↓ Serum urea, creatinine,</cell><cell cols="2">cystatin C 24 h post IRI</cell><cell>↓ Tubular damage 24 h</cell><cell>↑ GLP-1 and GLP-1R</cell><cell>↓ Tubular damage 72 h post IRI</cell><cell>Numerical reduction of serum</cell><cell>creatinine 72 h post IRI</cell><cell>↓ Serum creatinine 24 h and 72 h post IRI</cell><cell cols="2">↓ Tubular damage 24 and 72 h post IRI</cell><cell>↓ Inflammation/apoptosis/oxidative stress</cell><cell>↓ Serum creatinine 12 and 48 h post IRI</cell><cell>↓ Tubular necrosis 12 h post IRI, ↔ at</cell><cell cols="2">48 h post IRI</cell><cell>↓ Inflammation/apoptosis/oxidative stress</cell><cell>↑ Serum creatinine 24 h post IRI versus wildtype</cell><cell>↑ Tubular damage versus wildtype</cell><cell>↑ Macrophage infiltration versus wildtype</cell></row><row><cell>IRI</cell><cell></cell><cell cols="2">60 min IRI + UniNX</cell><cell></cell><cell></cell><cell></cell><cell cols="2">30 min bilateral IRI</cell><cell></cell><cell></cell><cell></cell><cell cols="2">30 min bilateral IRI</cell><cell></cell><cell></cell><cell cols="2">60 min bilateral IRI</cell><cell></cell><cell></cell><cell cols="2">60 min bilateral IRI</cell><cell></cell><cell></cell><cell cols="2">30 min IRI + UniNX</cell><cell>45 min IRI + UniNX</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>À1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Design</cell><cell cols="3">Healthy, female rats, À1 14 days, 5 mg•kg •day À1</cell><cell cols="2">pre IRI</cell><cell cols="3">Diabetic, male/female rats, À1 14 days, 5 mg•kg •day À1</cell><cell cols="2">pre IRI</cell><cell cols="2">Healthy, male rats, 5 mg•kg</cell><cell cols="2">5/22 h post IRI</cell><cell>Healthy, male rats,</cell><cell cols="2">3 days, 300/600 À1 mg•kg •day À1</cell><cell>post IRI</cell><cell cols="3">À1 •day À1 Healthy, male rats, 3 days, 600 mg•kg</cell><cell>post IRI</cell><cell cols="3">Healthy, male rats, À1 1/10 mg•kg</cell><cell>i.v. 15 pre IRI</cell><cell>DPP4 À/ À rats</cell></row><row><cell></cell><cell></cell><cell>Sitagliptin</cell><cell cols="2">Nuransoy et al. (2015)</cell><cell></cell><cell></cell><cell>Sitagliptin</cell><cell cols="2">Vaghasiya et al. (2011)</cell><cell></cell><cell cols="2">Sitagliptin</cell><cell cols="2">Youssef et al. (2015)</cell><cell></cell><cell>Sitagliptin</cell><cell>Chang et al. (2015)</cell><cell></cell><cell cols="2">Sitagliptin</cell><cell cols="2">Chen et al. (2013)</cell><cell></cell><cell>Vildagliptin</cell><cell cols="2">Glorie et al., 2012</cell><cell>DPP4 À/ À rats Daniel</cell><cell>et al. (2012) (Abstract)</cell></row></table><note><p><s>British Journal ofPharmacology (2017) 174 2273-2286 2283</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2276">British Journal of Pharmacology (2017) 174 2273-2286</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2017) 174 2273-2286 2277</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2017) 174 2273-2286 2279</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2017) 174 2273-2286 2281</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2282">British Journal of Pharmacology (2017) 174 2273-2286</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2017) 174 2273-2286 2285</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2286">British Journal of Pharmacology (2017) 174 2273-2286</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>B.H. received a research grant from Boehringer Ingelheim Pharma for this project.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declaration of transparency and scientific rigour</head><p><s>This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organisations engaged with supporting research.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The Concise Guide to PHARMACOLOGY 2015/16: Enzymes</title>
		<author>
			<persName><forename type="first">Sph</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fabbro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Marrion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Benson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="6024" to="6109" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Arsenijevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-F</forename><surname>Cajot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Dulloo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><surname>Montani</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Uninephrectomy in rats on a fixed food intake results in adipose tissue lipolysis implicating spleen cytokines</title>
	</analytic>
	<monogr>
		<title level="j">Front Physiol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">195</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences</title>
		<author>
			<persName><forename type="first">R</forename><surname>Baetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Corsini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1441" to="1467" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Pathophysiology of acute kidney injury</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Basile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Compr Physiol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1303" to="1353" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The link between acute kidney injury and chronic kidney disease</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Belayev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Palevsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Nephrol Hypertens</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="149" to="154" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Bloomfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Krishna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hreniuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hickey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bergman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="937" to="946" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Blydt-Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Katori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Iyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="745" to="754" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cellular pathophysiology of ischemic acute kidney injury</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Bonventre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="4210" to="4221" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">DPP-4 inhibitors: pharmacological differences and their clinical implications</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ceriello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sportiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rafaniello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rossi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Saf</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S57" to="S68" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leu</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors</title>
	</analytic>
	<monogr>
		<title level="j">Acta Pharmacol Sin</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="119" to="130" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The severity of acute kidney injury predicts progression to chronic kidney disease</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Chawla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Amdur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amodeo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Kimmel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Palant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1361" to="1369" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Chaykovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Von Websky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rahnenführer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heiden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuchs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e27861</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Exendin-4 and sitagliptin protect kidney from ischemiareperfusion injury through suppressing oxidative stress and inflammatory reaction</title>
		<author>
			<persName><forename type="first">Y-T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T-H</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-K</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L-T</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H-H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">270</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Coca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singanamala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Parikh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="442" to="448" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Connelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Bowskill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Advani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L-H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kabir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Invest Med</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">E172</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Experimental design and analysis and their reporting: new guidance for publication in BJP</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahluwalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Spa</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Giembycz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="3461" to="3471" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">CD26/ DPP4 deficiency impairs kidney function in the ischemia/reperfusion model in the rat. Poster (P351) presented at: 4. Jahrestagung der Deutschen Gesellschaft für Nephrologie</title>
		<author>
			<persName><forename type="first">C</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Hörsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Amann</surname></persName>
		</author>
		<idno>08.10.2012</idno>
		<ptr target="http://www.aey-congresse.com/nephrokongress2012/Sitzung.aspx?PSID=1921&amp;PAID=4866" />
	</analytic>
	<monogr>
		<title level="j">Hamburg. Germany. Available</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ellingsgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hauselmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Baggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Meier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1481" to="1489" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Endre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kellum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Somma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Koyner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference</title>
				<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page" from="30" to="44" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><surname>Field</surname></persName>
		</author>
		<title level="m">Discovering Statistics Using IBM SPSS Statistics</title>
				<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
		<respStmt>
			<orgName>SAGE: London, UK.</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Athyros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Elisaf</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Metab Toxicol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="787" to="812" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury</title>
		<author>
			<persName><forename type="first">Llf</forename><surname>Glorie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Verhulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Matheeussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Baerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Magielse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hermans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Renal Physiol</title>
		<imprint>
			<biblScope unit="volume">303</biblScope>
			<biblScope unit="page" from="F681" to="F688" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sharkovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pfab</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="87" to="93" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The risk of acute renal failure in patients with chronic kidney disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Ordoñez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Chertow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Mcculloch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Go</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="101" to="107" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Huan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Toxicol Methods</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="8" to="12" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Jungraithmayr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Meester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Matheeussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Arni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1166" to="1173" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kahles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Möllmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Diebold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Findeisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lebherz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="3221" to="3229" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Acute kidney injury: global health alert</title>
		<author>
			<persName><forename type="first">Kam Tao</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Burdmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nephropathol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="90" to="97" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Diagnostic criteria for acute kidney injury: present and future</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kellum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care Clin</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="621" to="632" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Animal research: reporting in vivo experiments: the ARRIVE guidelines</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kilkenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Browne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Cuthill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="1577" to="1579" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Kilkenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Browne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Cuthill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research</title>
	</analytic>
	<monogr>
		<title level="j">Osteoarthritis Cartilage</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="256" to="260" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Who regenerates the kidney tubule?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kramann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kusaba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Humphreys</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant gfu281</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="903" to="910" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Acute kidney injury associates with increased long-term mortality</title>
		<author>
			<persName><forename type="first">J-P</forename><surname>Lafrance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JASN</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="345" to="352" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Mcgrath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lilley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="3189" to="3193" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Dipeptidyl-peptidase IV (CD26) -role in the inactivation of regulatory peptides</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mentlein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Regul Pept</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="9" to="24" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Mulvihill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Drucker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Rev</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="992" to="1019" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Basic Statistics and Pharmaceutical Statistical Applications, Third edn</title>
		<author>
			<persName><forename type="first">Jed</forename><surname>Muth</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>CRC Press</publisher>
			<pubPlace>Boca Raton, FL, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakamaru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Akahoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Iijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hisanaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kume</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biopharm Drug Dispos</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="142" to="155" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1?</title>
		<author>
			<persName><forename type="first">P</forename><surname>Nambi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gellai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Prabhakar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="page" from="212" to="214" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene</title>
		<author>
			<persName><forename type="first">E</forename><surname>Noiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Romanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Romanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="74" to="82" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Protective effect of sitagliptin against renal ischemia reperfusion injury in rats</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nuransoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Beytur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Polat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Samdanci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sagir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Parlakpinar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ren Fail</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="687" to="693" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Padanilam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Hammerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="2133" to="2140" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hirose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Behrends</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="243" to="251" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Persy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Verstrepen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Ysebaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Greef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Broe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="601" to="611" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Persy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Verhulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Ysebaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Greef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Broe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="543" to="553" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Dealing with large sample sizes: comparison of a new one spot dot blot method to western blot</title>
		<author>
			<persName><forename type="first">Sed</forename><surname>Putra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tsuprykov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Websky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Reichetzeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lab</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1871" to="1877" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Nephrotoxic tubular and interstitial lesions: morphology and classification</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Racusen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Solez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Toxicol Pathol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="45" to="57" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sauvé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Momen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-Q</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Henkelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Husain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1063" to="1073" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Scheen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacokinet</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1" to="21" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure</title>
		<author>
			<persName><forename type="first">G</forename><surname>Schnapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hoevels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="7466" to="7477" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Acute kidney injury: preclinical innovations, challenges, and opportunities for translation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Silver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cardinal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Colwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Dickhout</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Kidney Health Dis</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">30</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands</title>
		<author>
			<persName><forename type="first">C</forename><surname>Southan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sharman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Benson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Faccenda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Pawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sph</forename><surname>Alexander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="D1054" to="D1068" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Incidence and outcomes of acute kidney injury in intensive care units: a veteran&apos;s administration study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Thakar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Christianson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Freyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Almenoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Render</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2552" to="2558" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eckhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Langkopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tadayyon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Himmelsbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="175" to="182" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes</title>
		<author>
			<persName><forename type="first">K</forename><surname>Timper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grisouard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Sauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Herzog-Radimerski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dembinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Peterli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="page" from="E1" to="13" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Timper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dalmas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dror</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rütti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thienel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Sauter</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells</title>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="165" to="179" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Substrate specificity to maintain cellular ATP along the mouse nephron</title>
		<author>
			<persName><forename type="first">S</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Endou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol</title>
		<imprint>
			<biblScope unit="volume">255</biblScope>
			<biblScope unit="page" from="F977" to="F983" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Acute renal failure in critically ill patients: a multinational, multicenter study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Uchino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kellum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bellomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Doig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Morimatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morgera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">294</biblScope>
			<biblScope unit="page" from="813" to="818" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vaghasiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sheth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bhalodia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Manek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Regul Pept</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="48" to="54" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Vercauteren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Ysebaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Greef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Eyskens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Broe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="2551" to="2561" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cadetg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ruf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mazzucchelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Redaelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1564" to="1573" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Y</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sakatsume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Narita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gejyo</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Expression, roles, receptors, and regulation of osteopontin in the kidney</title>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1645" to="1657" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Youssef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aaa</forename><surname>Mahmoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Abdelghany</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Pharmacol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="20" to="29" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Z-X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yin</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Osteopontin expressed in tubular epithelial cells regulates NK cellmediated kidney ischemia reperfusion injury</title>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="page" from="967" to="973" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
